NEW YORK, Dec. 18, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on VCEL, ZIOP, CERC, and CASI which is a click away at http://www.wallstequities.com/registration. Seeking Alpha reported that the sleepy Biotech M&A market should finally wake up in 2018. The article further noted that after months of uncertainty and wrangling, it looks like a tax bill will pass that will see huge tax discounts on the trillions of dollars stored by American companies overseas. Much of that capital has been gathering dust. Now that it will soon be repatriated, investors can anticipate a wave of M&A activity to be unleashed on the American market. In today's pre-market research, WallStEquities.com has issued research reports on Vericel Corp. (NASDAQ: VCEL), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Cerecor Inc. (NASDAQ: CERC), and CASI Pharmaceuticals Inc. (NASDAQ: CASI). Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at: http://www.wallstequities.com/registration
Vericel
Cambridge, Massachusetts headquartered Vericel Corp.'s shares rose 2.17%, finishing last Friday's session at $4.70. A total volume of 486,599 shares was traded. Over the last month and since the start of this year, the stock has surged 28.77% and 56.67%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 5.76% and 31.68%, respectively. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have a Relative Strength Index (RSI) of 53.82.
On December 07th, 2017, Vericel (VCEL) announced that it entered into an expanded $15-million term loan, and retained an existing $10-million revolving line of credit with Silicon Valley Bank and MidCap Financial Services, providing VCEL access to up to a total of $25 million of capital. The increased capital will support VCEL's planned MACI® (autologous cultured chondrocytes on porcine collage membrane) sales force expansion from 28 to 40 sales representatives and other marketing initiatives to support the continued growth in MACI uptake. Free Access to this morning's research report on VCEL at: http://www.wallstequities.com/registration/?symbol=VCEL
ZIOPHARM Oncology
On Friday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. ended the session 2.11% higher at $4.35. The stock recorded a trading volume of 3.52 million shares, which was above its three months average volume of 1.57 million shares. The Company's shares are trading below their 50-day moving average by 9.70%. Moreover, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 45.54.
On November 20th, 2017 at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology, ZIOPHARM Oncology announced positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, the Company's controlled human interleukin-12 gene therapy candidate for brain cancer. This gene therapy has demonstrated a targeted, anti-tumor immune response for the treatment of recurrent glioblastoma. Find your free research report ZIOP at: http://www.wallstequities.com/registration/?symbol=ZIOP
Cerecor
US-based Cerecor Inc.'s stock climbed 1.57%, to close the day at $1.94 with a total trading volume of 212,199 shares. The Company's shares have skyrocketed 74.77% in the last one month, 151.95% over the previous three months, and 120.35% since the start of this year. The stock is trading 55.51% and 136.48% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Cerecor, which develops treatments for patients suffering from nervous system disorders, have an RSI of 65.97. Sign up today for the free research report on CERC at: http://www.wallstequities.com/registration/?symbol=CERC
CASI Pharmaceuticals
Shares in Rockville, Maryland headquartered CASI Pharmaceuticals Inc. recorded a trading volume of 526,731 shares. The stock ended at $3.06, jumping 9.68% from the last trading session. The Company's shares have surged 16.35% in the past month, 63.64% over the previous three months, and 166.09% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 13.73% and 97.31%, respectively. Furthermore, shares of CASI Pharma, which focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China, have an RSI of 50.95. Wall St. Equities' research coverage also includes the downloadable free report on CASI at: http://www.wallstequities.com/registration/?symbol=CASI
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on VCEL, ZIOP, CERC, and CASI which is a click away at http://www.wallstequities.com/registration. Seeking Alpha reported that the sleepy Biotech M&A market should finally wake up in 2018. The article further noted that after months of uncertainty and wrangling, it looks like a tax bill will pass that will see huge tax discounts on the trillions of dollars stored by American companies overseas. Much of that capital has been gathering dust. Now that it will soon be repatriated, investors can anticipate a wave of M&A activity to be unleashed on the American market. In today's pre-market research, WallStEquities.com has issued research reports on Vericel Corp. (NASDAQ: VCEL), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Cerecor Inc. (NASDAQ: CERC), and CASI Pharmaceuticals Inc. (NASDAQ: CASI). Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at: http://www.wallstequities.com/registration
Advertisement
Vericel
Cambridge, Massachusetts headquartered Vericel Corp.'s shares rose 2.17%, finishing last Friday's session at $4.70. A total volume of 486,599 shares was traded. Over the last month and since the start of this year, the stock has surged 28.77% and 56.67%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 5.76% and 31.68%, respectively. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have a Relative Strength Index (RSI) of 53.82.
On December 07th, 2017, Vericel (VCEL) announced that it entered into an expanded $15-million term loan, and retained an existing $10-million revolving line of credit with Silicon Valley Bank and MidCap Financial Services, providing VCEL access to up to a total of $25 million of capital. The increased capital will support VCEL's planned MACI® (autologous cultured chondrocytes on porcine collage membrane) sales force expansion from 28 to 40 sales representatives and other marketing initiatives to support the continued growth in MACI uptake. Free Access to this morning's research report on VCEL at: http://www.wallstequities.com/registration/?symbol=VCEL
ZIOPHARM Oncology
On Friday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. ended the session 2.11% higher at $4.35. The stock recorded a trading volume of 3.52 million shares, which was above its three months average volume of 1.57 million shares. The Company's shares are trading below their 50-day moving average by 9.70%. Moreover, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 45.54.
On November 20th, 2017 at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology, ZIOPHARM Oncology announced positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, the Company's controlled human interleukin-12 gene therapy candidate for brain cancer. This gene therapy has demonstrated a targeted, anti-tumor immune response for the treatment of recurrent glioblastoma. Find your free research report ZIOP at: http://www.wallstequities.com/registration/?symbol=ZIOP
Cerecor
US-based Cerecor Inc.'s stock climbed 1.57%, to close the day at $1.94 with a total trading volume of 212,199 shares. The Company's shares have skyrocketed 74.77% in the last one month, 151.95% over the previous three months, and 120.35% since the start of this year. The stock is trading 55.51% and 136.48% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Cerecor, which develops treatments for patients suffering from nervous system disorders, have an RSI of 65.97. Sign up today for the free research report on CERC at: http://www.wallstequities.com/registration/?symbol=CERC
CASI Pharmaceuticals
Shares in Rockville, Maryland headquartered CASI Pharmaceuticals Inc. recorded a trading volume of 526,731 shares. The stock ended at $3.06, jumping 9.68% from the last trading session. The Company's shares have surged 16.35% in the past month, 63.64% over the previous three months, and 166.09% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 13.73% and 97.31%, respectively. Furthermore, shares of CASI Pharma, which focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China, have an RSI of 50.95. Wall St. Equities' research coverage also includes the downloadable free report on CASI at: http://www.wallstequities.com/registration/?symbol=CASI
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-biotech-stocks----vericel-ziopharm-oncology-cerecor-and-casi-pharma-300572465.html
SOURCE Wall St. Equities
